Patient Leaflet Updated 02-Apr-2024 | Glenmark Pharmaceuticals Europe Ltd
Pirfenidone 267, 534, 801 mg film-coated tablets
Pirfenidone 267 mg film-coated tablets
Pirfenidone 534 mg film-coated tablets
Pirfenidone 801 mg film-coated tablets
Pirfenidone
Keep this leaflet. You may need to read it again.
1. What Pirfenidone is and what it is used for
2. What you need to know before you take Pirfenidone
3. How to take Pirfenidone
4. Possible side effects
5. How to store Pirfenidone
6. Contents of the pack and other information
Pirfenidone contains the active substance pirfenidone and it is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults.
IPF is a condition in which the tissues in your lungs become swollen and scarred over time, and as a result makes it difficult to breathe deeply. This makes it hard for your lungs to work properly. Pirfenidone helps to reduce scarring and swelling in the lungs, and helps you breathe better.
If any of the above affects you, do not take Pirfenidone. If you are unsure ask your doctor or pharmacist.
Talk to your doctor or pharmacist before taking Pirfenidone
Pirfenidone may cause serious liver problems and some cases have been fatal. You will need a blood test before you start taking Pirfenidone and at monthly intervals for the first 6 months and then every 3 months thereafter whilst you are taking this medicine to check whether your liver is working properly. It is important that you have these regular blood tests for as long as you are taking Pirfenidone.
Do not give Pirfenidone to children and adolescents under the age of 18.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
This is especially important if you are taking the following medicines, as they may change the effect of Pirfenidone.
Medicines that may increase side effects of Pirfenidone:
Medicines that may reduce how well Pirfenidone works:
Do not drink grapefruit juice whilst taking this medicine. Grapefruit may prevent Pirfenidone from working properly.
As a precautionary measure, it is preferable to avoid the use of Pirfenidone if you are pregnant, planning to become pregnant, or think you might be pregnant as the potential risks to the unborn child are unknown.
If you are breast-feeding or plan to breast-feed speak to your doctor or pharmacist before taking Pirfenidone. As it is unknown whether Pirfenidone passes into breast milk, your doctor will discuss the risks and benefits of taking this medicine while breast-feeding if you decide to do so.
Do not drive or use machines if you feel dizzy or tired after taking Pirfenidone.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Treatment with Pirfenidone should be started and overseen by a specialist doctor experienced in the diagnosis and treatment of IPF.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Your medicine will usually be given to you in increasing doses as follows:
The recommended maintenance daily dose of Pirfenidone is 801 mg (3 yellow tablets or 1 brown tablet) three times a day with food, for a total of 2403 mg/day.
Swallow the tablets whole with a drink of water, during or after a meal to reduce the risk of side effects such as nausea (feeling sick) and dizziness. If symptoms continue, see your doctor.
Dose reduction due to side effects
Your doctor may reduce your dose if you suffer from side effects such as, stomach problems, any skin reactions to sunlight or sun lamps, or significant changes to your liver enzymes.
Contact your doctor, pharmacist or nearest hospital casualty department immediately if you have taken more tablets than you should and take your medicine with you.
If you forget a dose, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose. Each dose should be separated by at least 3 hours. Do not take more tablets each day than your prescribed daily dose.
In some situations, your doctor may advise you to stop taking Pirfenidone. If for any reason you have to stop taking Pirfenidone for more than 14 consecutive days, your doctor will restart your treatment with a dose of 267 mg 3 times a day, gradually increasing this to a dose of 801 mg 3 times a day.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Pirfenidone and seek medical attention immediately if you notice any of the following symptoms or signs
Talk to your doctor if you get any side effects.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.co.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle label, blister and carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Pirfenidone 267/534/807 mg film-coated tablets are packaged in blisters composed by PVC/Aclar–Aluminium, opaque PVC/Aclar-Aluminium, PVC/Aluminium & PVC/PVdC – Aluminium.
Pirfenidone 267 mg film-coated tablets: yellow, oval-shaped, approximately 13.15 x 6.15 mm biconvex film coated tablets, plain on both sides.
The blister packs contain 21, 30, 60, 84, 90, 250, 270, 63 (2-week treatment initiation pack) or 252 (Continuation pack) film-coated tablets.
Pirfenidone 534 mg film-coated tablets: orange, oval-shaped, approximately 16.25 x 8.45 mm biconvex film coated tablets, plain on both sides.
The blister packs contain 21, 30, 60, 63, 84, 90, 250, 252, 270 film-coated tablets.
Pirfenidone 801 mg film-coated tablets: brown, oval-shaped, approximately 20.15 x 9.45 mm biconvex film coated tablets, plain on both sides.
The blister packs contain 21, 30, 60, 63, 84, 90, 250, 270 or 252 (Continuation pack) film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
This leaflet was last revised in March 2024.
Building 2, Croxley Park, Watford, WD18 8YA
+44 (0)1923 251137
www.glenmarkpharma.com
+44 (0)1923 202 950
0800 458 0383
+44 (0)1923 202 950